Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 9/20 | 0.49 |
| ▸ | MMP1 | P03956 | 4/20 | 0.49 |
| ▸ | MMP3 | P08254 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12705747 | 1.00 | TSHR (0.50) | TSHRLMNAALDH1A1MMP2MMP1 | |
| SCHEMBL23541614 | 0.99 | TSHR (0.49) | TSHRLMNAALDH1A1MMP2MMP1 | |
| SCHEMBL807262 | 0.94 | TSHR (0.50) | TSHRALDH1A1MMP2MMP1MMP3 | |
| SCHEMBL27948430 | 0.89 | TSHR (0.50) | TSHRLMNAALDH1A1MMP2MMP1 | |
| SCHEMBL807265 | 0.88 | POLB (0.51) | TSHRLMNAALDH1A1RAB9APOLB | |
| SCHEMBL18202478 | 0.88 | POLB (0.51) | TSHRLMNAALDH1A1RAB9APOLB | |
| SCHEMBL11676190 | 0.86 | TACR1 (0.58) | ALDH1A1POLB | |
| SCHEMBL28848015 | 0.86 | BCHE (0.48) | TSHRLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL11676193 | 0.86 | TACR1 (0.58) | ALDH1A1POLB | |
| SCHEMBL13960042 | 0.86 | TACR1 (0.58) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | TSHR 4863/4885LMNA 2405/4885ALDH1A1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.